Writing US FDA-acceptable Clinical Trial Protocols

SKU: CLIO0002 Category:

Purchase Options

Writing US FDA-acceptable Clinical Trial Protocols – Live Access
$250.00

Out of stock

Writing US FDA-acceptable Clinical Trial Protocols – Recorded Access
$300.00

Out of stock

Writing US FDA-acceptable Clinical Trial Protocols – Training CD/DVD
$450.00

Out of stock

Writing US FDA-acceptable Clinical Trial Protocols – USB Flash Drive
$550.00

Out of stock

Writing US FDA-acceptable Clinical Trial Protocols – Live+Recorded Access
$550.00

Out of stock

Writing US FDA-acceptable Clinical Trial Protocols – Live Access+CD/DVD
$700.00

Out of stock

Writing US FDA-acceptable Clinical Trial Protocols – Live Access+USB Flash Drive
$900.00

Out of stock

The clinical trial protocol is a multi-dimensional document that plays a critical role in the success of a clinical trial. There are many schools of thought about the best approach to writing a clinical trial protocol depending on individuals or organizations sponsoring a given clinical trial.

Per FDA and ICH guidelines, a clinical protocol should be based on sound scientific rationale, conducted in a suitable population, include all appropriate procedures that help meet the endpoints, and be protective of study participants both physically and ethically. On an average about one of every three clinical trials fail to meet their primary goals due to poor design, faulty statistical strategy, lower recruitment, poor management of resources, and regulatory issues. Most of these causes of failure can be mitigated by a well-designed clinical trial protocol.

Irrespective of the Phase of a study, clinical trial protocols should follow some common rules. These rules are based on regulatory requirements, scientific logic, and practical experience. This webinar will walk the attendee through 10 critical steps in the development of a clinical protocol. Step-by-step instructions will be provided, with case studies to emphasize the common mistakes and potential solutions.

Why Should you Attend:
If you are involved in writing a clinical trial protocol, this webinar will provide valuable suggestions about various aspects of a clinical protocol from initial synopsis to various elements of the protocol, role of various personnel in finalizing the protocol, and troubleshooting common issues. The basic elements of a clinical trial protocol, the dos and don’ts of clinical trial procedures, development of a new protocol, amending protocols, scientific and ethical review of clinical protocols will be discussed. Also discussed will be role of interactions with the FDA, global clinical trials, and projected trends for the near future.

Objectives of the Presentation:
At the end of this webinar, you would understand:

  • The overall structure of a protocol and regulatory requirements
  • Identify who contributes to the protocol development and amendments
  • The element of a protocol such a background scientific rationale, design (single blind, double blind, randomized, etc.), primary and secondary endpoints, inclusion/exclusion criteria, the Schedule of Events, adverse event management, statistical parameters, informed consent, and study synopsis
  • Practical issues with protocol writing such a differences in various phases of clinical trials, the protocol review process, using key opinion leaders, and using public resources and templates
  • Common issues with FDA and IRB approval of clinical protocols.

Who can Benefit:

  • Sponsors of INDs
  • Regulatory Affairs Professionals
  • Senior Management Executives (CEO, COO, CFO, etc)
  • Drug Discovery and Development Professionals (R&D and CMC)
  • Clinical Trial Managers
  • Project Managers and Clinical Trial Specialists
  • Regulatory Compliance Associates and Managers
  • People investing in FDA-regulated product development projects.

Instructor Profile:

Mukesh Kumar

Mukesh Kumar

Mukesh Kumar, leads the Regulatory Affairs and Quality Assurance departments at Amarex Clinical Research, a full service CRO based in Germantown, MD. His key expertise is in developing Global Regulatory Business Strategies for biomedical product development and his passion is to bring traditional therapies for India, China and the Latin-America to the Western markets. In addition to regulatory expertise, Mukesh is an experienced auditor and a trainer in regulatory and business processes.

Mukesh started his professional career as a research scientist at the NIH, Baylor College of Medicine, Houston, and several premier institutions in India. With more than 11 years of experience in virology, gene therapy, and molecular biology, Mukesh has expertise in biological and combination products. He has been a global Regulatory Affairs Specialist (US, EU, and India) for the last 5 years. He has filed several new-INDs for drugs, biologics and combinations products, NDAs, 510K, PMAs, etc. He has made several hundred FDA submissions, and arranged a number of meetings and responses to FDA comments. In addition, he has had made regulatory submission in the EU and India. Mukesh has reviewed/compiled more than 100 clinical trial protocols and has supervised more than 60 multi-national clinical trials (both under IND and non-IND trials), in the US, Canada, Latin America, Africa, and Asia. In addition to drugs and Biologics, he has extensive experience in medical device and diagnostic product regulatory filings and safety monitoring.

Specialties: Technology transfer, global regulatory strategy, global clinical trials, safety reporting, training, and GLP/GCP audits.

Honors and Awards: US patent awarded “Gene Therapy vectors derived from Sendai virus”.

Education: Education: Delhi University – Ph.D., Biochemistry – 1993 – 1997
National Dairy Research Institute – MS, Biochemistry – 1990 – 1993

READ MORE

Reviews

There are no reviews yet.

Be the first to review “Writing US FDA-acceptable Clinical Trial Protocols”

Your email address will not be published. Required fields are marked *